←
Angus Liu127 posts
Angus Liu avatar

Angus Liu

@Angus_Fierce

Biopharma reporter @FiercePharma & @FierceBiotech. Medill MSJ 16

◷ Joined November 2013▧ 2 Photos and videos
Angus Liu avatar
Angus Liu@Angus_Fierce·Oct 28

As Enhertu sweeps across the entire HER2 breast cancer treatment landscape, the big question facing the industry is: What comes next? Here's a deep dive #BCAM fiercebiotech.com/biotech/ad…

FiercePharma avatar
⟳ Angus Liu retweeted
FiercePharma@FiercePharma·Oct 24

Amgen’s Imdelltra drives massive survival benefit in ‘watershed moment’ for small cell lung cancer. #ESMO26 fiercepharma.com/pharma/amge…

Angus Liu avatar
Angus Liu@Angus_Fierce·Sep 11

In his first interview as FDA's oncology chief, Dr. Angelo de Claro vows to "continue the innovation that the OCE is known for." fiercepharma.com/pharma/firs…

Angus Liu avatar
Angus Liu@Angus_Fierce·Aug 26

Akeso CEO agrees that $SMMT needs a Big Pharma partner to back ivonescimab. FYI, $MRK just pubbed the first global trial for its PD-1xVEGF on registry: a solid tumor ph.2 with sac-TMT fiercepharma.com/pharma/akes…

Angus Liu avatar
Angus Liu@Angus_Fierce·Jul 29

Merck briefly posted—and then rapidly deleted—a new trial listing testing its PD-1xVEGF bispecific (MK-2010) combined with its TROP2 ADC (sac-TMT). fiercebiotech.com/biotech/me…

Angus Liu avatar
Angus Liu@Angus_Fierce·Jul 23

89% PFS, 62% OS improvements from J&J's MonumenTAL-6 trial for bispecific doublet Tecvayli and Talvey in 2L+ multiple myeloma. fiercepharma.com/pharma/jj-b…

Angus Liu avatar
Angus Liu@Angus_Fierce·Jun 24

After a 4-month investigation, Nature has decided to retract viral PD-1 study that tied lung cancer survival to treatment timing fiercepharma.com/pharma/natu…

Angus Liu avatar
Angus Liu@Angus_Fierce·May 31

#ASCO26: For Akeso's HARMONi-6, ivonescimab's 34% overall survival improvement versus PD-1 inhibitor in their chemo combos in first-line squamous NSCLC draws both hope and scrutiny at #ASCO2026 fiercepharma.com/pharma/asco…

FierceBiotech avatar
⟳ Angus Liu retweeted
FierceBiotech@FierceBiotech·Apr 17

Merck's first PD-1xVEGF bispecific data are here: 55% unconfirmed ORR in a small group of first-line NSCLC patients #AACR26 fiercebiotech.com/biotech/me…

Angus Liu avatar
Angus Liu@Angus_Fierce·Mar 2

In other words, FDA still took the full standard 60-day filing review period for a CNPV, even though this is an sNDA of an existing drug filed under RTOR, which means the review should have started before the entire submission package was completed.

Angus Liu avatar
Angus Liu@Angus_Fierce·Mar 2

The FDA's press release says zongertinib's application was FILED on Jan. 13, 2026. But Boehringer told us that they actually completed the package under real-time oncology review on Nov. 14, 2025, and that it was ACCEPTED on Jan. 13.

A new first line standard of care for HER2 mutant NSCLC? Zongertinib receives accelerated approval as initial therapy based on Beamion LUNG-1 trial with 1L RR 76%. Part of the new FDA voucher program, approval granted 44 days after filing! fda.gov/news-events/press-an…

Angus Liu avatar
Angus Liu@Angus_Fierce·12 Nov 2025

FDA unveils ‘plausible mechanism pathway,’ a new approach that could trigger a seismic shift in how bespoke gene editing therapies are developed and approved. fiercebiotech.com/biotech/fd…

FiercePharma avatar
⟳ Angus Liu retweeted
FiercePharma@FiercePharma·8 Sep 2024

Akeso, Summit's ivonescimab crushes Merck's Keytruda in China study, signaling potential new standard of care in lung cancer #WCLC24 fiercepharma.com/pharma/akes…